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1.0  INTRODUCTION 
 
Men’s health has been recognized as a significant health problem in the 
world since the late twentieth century. Prostate cancer (PCa) and benign prostatic 
hyperplasia (BPH) are common urologic conditions in elderly men (Miah and Catto, 
2014). In Malaysia, the state of Malaysian men’s health is worrisome for several 
years and the cancer-related death is also becoming a major health issue with an 
increasing incidence in colorectal, lung, laryngeal as well as prostate cancers (Tong 
et al., 2011). 
 
Globally, the incidence of PCa has increased dramatically in recent years, 
mostly due to an aging population, the practice of prostate specific antigen (PSA) 
screening test and subsequent prostate biopsy. Worldwide, PCa is the second most 
prevalent cancer diagnosis and it became the sixth leading cause of cancer mortality 
in men, with a global incidence of 14% (903,500) of the total new cancer  cases and 
6% (258,400) of the total cancer deaths in men in 2008,  according to the WHO 
GLOBOCAN database (Jemal et al., 2011). Of the number, about 14% were 
diagnosed within Asia Pacific region (Baade et al., 2013).  
 
Specifically in Malaysia, there were a total of 502 PCa cases diagnosed in 
2007 and reported to National Cancer Registry (NCR), and it became the fourth 
most common cancer among men. The incidence increases after 45 years old and 
raised abruptly after the age of 60 with the overall age-standardized incidence of 6.2 
per 100,000 populations. It was highest among the Indians followed by Chinese and 
Malay (Omar and Tamin, 2011). A more recent audit of cancer cases treated at a 
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tertiary center in Malaysia in 2008 found that the PCa treated also increased from 
fewer than four cases treated in 2000 to 25 cases in 2007 (Othman et al., 2008). 
 
 The exact causes of PCa are remains unclear (Baade et al., 2013). 
Currently, the main diagnostic tools for PCa include digital rectal examination (DRE), 
serum PSA level and transrectal ultrasonography (TRUS). However the definitive 
diagnosis is depends on the histopathologic verification of adenocarcinoma in 
prostate specimens, either from biopsy cores or operative specimens (Heidenreich 
et al., 2012). Few previous studies suggest that inhibition of apoptosis is an 
important element in pathogenesis of PCa and it might also occur in BPH 
(Krajewska et al., 2003; Novara et al., 2006; Rodríguez-Berriguete et al., 2010; 
Shariat et al., 2005; Tu et al., 1996). 
 
Gleason score and cancer stage at the time of diagnosis still remain the gold 
standards to help for prognostication of prostate cancer (Flavin et al., 2011). 
However, there are evidences suggesting that survivin expression in cancer cells is 
associated with clinicopathologic variables of aggressive disease and may represent 
an important prognostic marker for patient outcome (Shariat et al., 2004). Clinicians 
have limited ability to estimate survival in patients with newly diagnosed prostate 
cancer, and uncertainty therefore exists about optimal treatment decisions, 
especially for men with localized disease (Concato et al., 2009).   
 
This study will investigate the expression of survivin in PCa and BPH and its 
clinical significance in PCa patients.  
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2.0 LITERATURE REVIEW 
 
2.1 Prostate Gland  
 
In order to understand prostate cancer (PCa), it is helpful to know about the 
prostate and nearby structures in the body. The prostate is a chestnut-shaped gland 
of the male reproductive system. Anatomically, it is located below the neck of urinary 
bladder and in front of the rectum. The size of the prostate changes with increasing 
age. In younger men, it is about the size of a walnut and weighs about 30 grams, but 
it can be much larger in older men. The main function of the prostate is to secrete a 
slightly alkaline fluid that forms part of the seminal fluid, a fluid that carries sperm. 
Just behind the prostate are glands called seminal vesicles that make most of the 
fluid for semen. The urethra, the tube that carries urine and semen out of the body 
through the penis, goes through the centre of the prostate (Prostate Cancer 
Overview, 2015).  
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Figure 2.1: Anatomy of prostate gland. Source: Prostate Cancer Overview, 2015. 
  
The prostate gland is divided into 3 zones; peripheral, transitional and central 
zone. The peripheral zone is the area that closest to the rectum, constitutes the 
largest zone of prostate gland. It can easily palpable by clinician during DRE. The 
majority of prostate cancer (approximately 70%) are found in the peripheral zone 
(Crawford, 2009), while about 25% arises in the transitional zone (Schenk et al., 
2011). The transitional zone is the middle area of the prostate, between peripheral 
and central zone. This zone makes up about 20% of the prostate gland until the age 
of 45 to 50 years. As men age, it may begin to undergo varying degree of 
enlargement stimulated by testosterone until it become the largest area of the 
prostate. This process called benign prostatic hyperplasia (BPH) (Medifocus.com 
and Jacob, 2012). Almost all BPH arises in the transitional zone (Schenk et al., 
2011). The central zone is the part that is farthest from the rectum. In view of this, 
prostate cancer that develops in this zone cannot be felt by the clinician during a 
DRE. 
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Figure 2.2: Different zones of prostate gland. Source: Crawford, 2009. 
 
The prostate starts to develop before birth. It grows rapidly during puberty, 
fuelled by male hormones called androgens. The main androgen namely 
testosterone, is made in the testicles. The enzyme 5-alpha reductase converts 
testosterone into dihydrotestosterone (DHT). DHT is the main hormone that signals 
the prostate to grow. The prostate usually stays at about the same size or grows 
slowly in adults, as long as male hormones are present. 
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2.2: Prostate cancer  
 
There are several types of cells that are found in the prostate, but 95% of all 
prostate cancers develop from the gland cells. The medical term for a cancer that 
starts in gland cells is adenocarcinoma. The remaining 5% of PCa cases include 
squamous cell carcinomas, including sarcomas, small cell carcinomas, and 
transitional cell carcinomas (Medifocus.com and Jacob, 2012). Thus, any PCa it is 
almost certain to be an adenocarcinoma.  
 
2.2.1: Risk factors  
 
The factors that determine the risk of developing clinical PCa are remain 
unclear (Baade et al., 2013). However there are few well-established risk factors 
have been identified; increasing age, ethnicity, family history as well as saturated fat 
diet (Flavin et al., 2011; Heidenreich et al., 2011). 
 
Most cases of PCa were diagnosed in men aged between 50 to 79 years old 
(Baade et al., 2013). In Malaysia, the incidence of PCa (Figure 2.3) raised 
instantaneously after the age of 60 (Omar and Tamin, 2011). The age-standardized 
incidence (ASR) of PCa by ethnicity in United State was highest among black men, 
followed by white men; and lower among men of Hispanic and Asian/Pacific Islander 
(Crawford, 2009). In Malaysia, the ASR was highest among Indians (8.7 per 
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100,000), followed by Chinese (5.8 per 100,000) then Malay (4.9 per 100,000) 
(Omar and Tamin, 2011). 
 
 
 
Figure 2.3: Age-specific Cancer Incidence per 100,000 population by sex, Malaysia 
2007. Source: Omar and Tamin, 2011. 
 
According to Heidenreich et al. (2011), if one first-line relative is affected, the 
risk for a man to develop PCa is at least doubled. The risk increases 5 to 11-fold, if 
two or more first-line relatives have the disease. However, only about 9% of 
individuals with PCa have true hereditary PCa. True hereditary PCa is defined as 
three or more relatives have PCa, or at least two who developed PCa at early onset 
(i.e less than 55 years old). 
 
According to Shahar et al. (2011), the protective factors for PCa include high 
intake of fruits and vegetables, low fat diet and being physically active at middle age.  
Her study suggested that vegetables of specific family groups, low fat diet and 
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consumption of fruits; and a total serving of more than three serving per day might 
protect against oxidative DNA damage and subsequently decrease the risk of PCa 
development. A positive association of PCa risk and total fat intake was found in all 
ethnic groups (Whittemore et al., 1995). Therefore, it is essential for Malaysian men 
to consume adequate fruits and vegetables, reduce fat intake and engage in 
physical activity in order to reduce risk of PCa (Shahar et al., 2011). 
 
Cigarette smoking is well known to cause of human malignancies such as 
lung cancer and has been associated with the development of many other cancers 
like bladder, breast, oesophagus and kidney cancer (Othman et al., 2008). However, 
Matzkin and Soloway (1993) reviewed the literatures on the effects of cigarette 
smoking on PCa have found conflicting reports. The consequences of cigarette 
smoking on PCa are inconclusive and difficult to interpret; some studies indicate no 
association whereas others suggest an elevated risk among smokers (Giovannucci 
et al., 1999). Thus, the data are not convincing that cigarette smoking results in a 
higher risk of PCa (Haas and Sakr, 1997). 
 
2.2.2: Signs and symptoms 
 
The extent of disease severity in PCa is highly variable. It may range from 
indolent to aggressive disease. Some men with PCa have life span similar to the 
general population; in contrast others develop metastatic disease that can lead to 
death within months (Concato et al., 2009). PCa presentation is commonly 
asymptomatic. But once the symptoms are noticed, it usually advocates an 
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advanced stage of PCa (Dasgupta et al., 2012). PCa commonly presents with lower 
urinary tract symptoms (LUTS) or prostatism symptoms such as hesitancy, nocturia, 
posterior dribbling, unsatisfactory voiding, incontinence, dysuria and haematuria due 
to blockage of the lower urinary tract by swollen prostate gland. However, symptoms 
of advanced PCa include dull and deep pain in the pelvic, lower back or upper thigh, 
weight loss, loss of appetite and fatigue. 
 
In general, PCa is a slow-growing malignancy that needs a long 
development period (Rodríguez-Berriguete et al., 2010). Many of them are present 
for years as latent neoplasms that are evident only histologically before the clinical 
diagnosis of PCa (Haas and Sakr, 1997). One of the reasons is that most of PCa 
cases (about 70%) started in the peripheral zone (Crawford, 2009). 
 
The duration from the first histologically identifiable form of PCa until 
clinically evident cancer is not known, but it probably highly varies. For the small 
subset of all histologic cancers that discovered clinically during the lifespan of the 
individual, studies of tumour doubling time indicate that this process may take more 
than 10 to 15 years (Haas and Sakr, 1997). 
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2.2.3: Screening and diagnosis of prostate cancer 
 
According to World Health Organization (WHO) guidelines, the ideal 
screening test for PCa is the test should be minimally invasive, easily available and 
easily performed, accurate, acceptable to the general population, and significantly 
affects outcomes of the disease, for example mortality rate (Djavan et al., 2011).  
 
European Association of Urology guideline (2015) has suggested a baseline 
PSA testing for men who are at risk of having PCa, which include men more than 50 
years, or men aged more than 45 years with family history of PCa, or African-
Americans. Men with serum PSA level >1 ng/mL at 40 years old and >2 ng/mL at 60 
years old are also at higher risk of PCa metastasis or death few decades later 
(Mottet et al., 2015). PSA testing in men older than 75 years is not recommended 
because its early detection would not have any clinical impact (Heidenreich et al., 
2012). 
 
The main diagnostic tools for PCa include digital rectal examination (DRE), 
serum prostate specific antigen (PSA) level and transrectal ultrasound (TRUS); 
however the definitive diagnosis is depends on histopathologic verification of 
prostate adenocarcinoma in prostate specimens, either from biopsy cores or 
operative specimens (Heidenreich et al., 2011).  
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2.2.4: Gleason score 
 
The Gleason grading system is an important prognostic factor in PCa. The 
International Society of Urological Pathology (ISUP) system is clinically useful for 
determining the most appropriate treatments for patients with early stage PCa 
(Uemura et al., 2009). The 2005 ISUP Modified Gleason system is the current 
standard for grading prostate adenocarcinoma on needle core biopsy and operative 
specimens. The Gleason system was introduced in1966. It has undergone series of 
modification and upgrading until in 2005, the ISUP had convened a conference in an 
attempt to achieve consensus in controversial areas regarding Gleason system. 
This conference yield the 2005 ISUP Modified Gleason System (Montironi et al., 
2010).   
 
Gleason grading describes the degree of aggressiveness of the tumor by 
determining its degree of differentiation based on the appearance of the tissue 
under a microscope. It is an architectural grading system that ranges from well 
differentiated (grade 1) to poorly differentiated (grade 5) (Stark et al., 2009). The 
Gleason score is the sum of the two highest grades assigned to two tissue areas 
extracted during the biopsy. The score is ranging from 2 (1+1) to 10 (5+5). A high 
Gleason grade (8-10) does indicate a greater chance that the cancer has spread 
beyond the prostate and is more aggressive type of cancer (Montironi et al., 2010). 
In core biopsies, the worst grade should always be incorporated in the Gleason 
score, even if comprising < 5% of the cancer (Heidenreich et al., 2012). 
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2.2.5: Staging  
 
Staging is the method used by clinician to evaluate how far the cancer has 
spread once it has been diagnosed. It plays an important role in determining both 
the treatment options and predicting the prognosis. The most widely used staging 
system for PCa is the American Joint Committee on Cancer (AJCC) TNM system. 
The decision to proceed with further diagnostic or staging workup is guided by which 
the treatment options are available to the patient, and considering the patient’s 
preference, age and comorbidity (Heidenreich et al., 2011). 
 
The TNM system for PCa is based on 5 key elements: 
• The extent of the primary tumor (T category) 
• Whether the cancer has spread to nearby lymph nodes (N category) 
• The absence or presence of distant metastasis (M category) 
• The PSA level at the time of diagnosis 
• The Gleason score, based on the prostate biopsy (or surgery) 
 
Based on American Cancer Society (ACS), there are 2 types of staging for 
prostate cancer; clinical stage and pathologic stage. The clinical stage is the 
clinician’s best estimate of the extent of the PCa, based on the physical exam 
including DRE, laboratory tests, prostate biopsy, and any imaging. Whereas, the 
pathologic stage is based on the surgery and examination of the removed tissue. 
This means that after surgery, the stage of the PCa might actually change afterward. 
Pathologic staging is likely to be more accurate than clinical staging, as it allows the 
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clinician to get a first-hand impression of the extent of the disease. Both types of 
staging use the same categories (but the T1 category is only used for clinical 
staging). 
 
 
 
Figure 2.4: AJCC Prostate Cancer Staging. Source: http://www.cancer.org. 
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Once the T, N, and M categories have been determined, this information is 
combined, along with the Gleason score and serum PSA level, in a process 
called stage grouping. If the Gleason score or PSA results are not available, the 
stage can be based on the T, N, and M categories. The overall stage is expressed in 
Roman numerals from I (the least advanced) to IV (the most advanced). This is 
done to help determine treatment options and the prognosis. 
 
 
 
Figure 2.5: Stage grouping, AJCC Prostate Cancer Staging. Source: 
http://www.cancer.org 
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Table 2.1:  Risk groups for biochemical recurrence of localised and locally advanced 
prostate cancer 
 
Source: Mottet et al., 2015. 
 
2.2.6: Metastasis 
 
Metastatic cancer is cancer that has spread from the place where it first 
started to another place in the body. It consists of series of sequential interrelated 
steps that lead to spread of the disease to distant organs such as bone, lymph 
nodes, rectum, urinary bladder, and brain, which ultimately leads to death (Dasgupta 
et al., 2012). Hematogenous metastases were present in 35% of 1,589 patients with 
PCa, with most frequent involvement being bone (90%), lung (46%), liver (25%), 
pleura (21%), and adrenals (13 %) (Bubendorf et al., 2000). 
 
2.3: Benign prostatic hyperplasia 
 
Benign prostatic hyperplasia (BPH) is a common problem among older men, 
which responsible for significant morbidities (Cunningham et al., 2014).  The 
prevalence of BPH rises markedly with age (Patel and Parsons, 2014). The 
Malaysia Ministry of Health has reported that the prevalence of BPH is about 60% in 
men above 60 years and rise up to 82% in men aged 71 to 80 years (Ministry of 
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Health, 2002). In Malaysia, the prevalence increased 8% per decade from 41.7% for 
men aged 50 to 59 to 65.4% for men aged 70 or more (Teh et al., 2001). Many 
observational studies done in Europe, United State and Asia have demonstrated 
that older age is a risk factor for BPH onset and clinical progression (Patel and 
Parsons, 2014). BPH and PCa are often found concurrently, and the diagnosis of 
PCa is frequently made during the evaluation of obstructive symptoms associated 
with BPH (Haas and Sakr, 1997). 
 
BPH is a histological diagnosis associated with unregulated proliferation of 
primarily stromal that composed of connective tissue and smooth muscle; and 
glandular epithelium within the prostate transition zone (Auffenberg et al., 2009). In 
BPH, cellular proliferation leads to increased prostate volume and increased stromal 
smooth muscle tone (Patel and Parsons, 2014).  
 
The most common presentation of BPH is the collection of symptoms 
described as LUTS which includes voiding symptoms (poor stream, hesitancy, 
terminal dribbling, and feeling of incomplete emptying) and storage symptoms 
(urgency, frequency and nocturia). Less frequently, BPH has been associated with 
other comorbidities including acute urinary retention, renal insufficiency, 
development of bladder calculi, urinary incontinence, and recurrent urinary tract 
infection (Auffenberg et al., 2009). 
 
The risk factors that has been identified are increasing age, severity of LUTS 
symptoms (IPSS >7), low maximum flow rate (<12 mL/s), prostate size and 
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significant residual urine volume (Li et al., 2008). Other factors include chronic 
prostatitis, metabolic syndrome, obesity and genetic component to BPH (Vuichoud 
and Loughlin, 2015).  
 
BPH is usually diagnosed clinically by evaluation of LUTS and DRE to 
assess prostate volume, prostate nodularity and asymmetry. But, DRE has low 
sensitivity and tends to underestimate the prostate volume (Vuichoud and Loughlin, 
2015). There are two internationally validated scoring systems that can be used to 
assess severity of LUTS objectively; the AUA-SI (American Urological Association-
Symptoms Index) and the IPSS (International Prostate Symptoms Score), which are 
useful in BPH management (Vuichoud and Loughlin, 2015). 
 
2.4: Pathophysiology of prostate cancer and benign prostatic hyperplasia 
 
Prostate cancer (PCa) and benign prostatic hyperplasia (BPH) are common 
urologic conditions in older men (Miah and Catto, 2014). PCa and BPH frequently 
coexist whereby more than 20% of PCa patients also have underlying BPH, and 10-
20% of PCa is found incidentally in surgically removed BPH specimens (Schenk et 
al., 2011).  
 
The precise etiology for both conditions is not well understood (Baade et al., 
2013; Vuichoud and Loughlin, 2015). However, these two conditions have several 
similarities whereby the prevalence of both PCa and BPH increases with age, both 
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are androgen-dependent, both respond to androgen-deprivation treatments, both 
share similar genetic and epigenetic alterations and inflammatory components which 
contribute to both conditions (Schenk et al., 2011).  
 
 Despite these similarities, a causal relationship between them has not been 
established (Miah and Catto, 2014). Differences in the anatomic location and 
histology of these two conditions provide the evidence that BPH does not affect PCa 
risk (Schenk et al., 2011). 
 
The development and progression of PCa needs a long duration, probably 
due to the evolution of normal prostate through phases of prostatic intraepithelial 
neoplasia (PIN) and possibly other atypical proliferating lesions before producing 
PCa (De Marzo et al., 1999; Rodríguez-Berriguete et al., 2010). However, 
development of BPH does not involve PIN, rather it is an overgrowth of both stromal 
and epithelial components (De Marzo et al., 1999).  
 
The correct balance between apoptosis and inhibition of apoptosis (Figure 
2.6) preserves normal homeostasis and organ morphogenesis and deviations of this 
process can cause some human diseases such as cancer, autoimmune disease and 
neurodegenerative disorders (O'Driscoll et al., 2003). 
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Figure 2.6: Uncontrolled cellular proliferation due to disruption of the normal balance 
between proliferation and apoptosis. (A) indicates normal prostate physiology when 
a steady state equilibrium exist between proliferation and apoptosis. (B) indicates 
pathophysiological conditions when the rate of cellular proliferation exceeds the rate 
of apoptosis. Source: Chatterjee, 2003. 
 
In prostate carcinogenesis, few previous studies suggest that inhibition of 
apoptosis is a critical element that contributes to it pathogenesis, rather than 
enhanced cellular proliferation (Krajewska et al., 2003; Tu et al., 1996). Several in 
vitro studies also suggested that a reduction of apoptosis might occur in BPH 
(Novara et al., 2006). Rodríguez-Berriguete et a. (2010) demonstrated the 
immunoreaction to inhibitor of apoptosis c-IAP1/2, c-IAP-2, ILP-2, NAIP, survivin, 
XIAP, p-Elk-1, p-ATF-2 and NF-kB in BPH tissue, which provoke the lower 
apoptosis index in BPH.  Similar results have been reported to survivin (Shariat et 
al., 2005). 
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2.5:  Inhibitor of apoptosis proteins (IAPs) 
 
IAP is a gene family that characterized by presence of baculovirus IAP 
repeat (BIR) domain that plays an important role in the negative regulation of 
apoptosis (O'Driscoll et al., 2003). In human, eight members of IAPs family have 
been identified comprises namely Survivin, XIAP (ILP-1), c-IAP-1, c-IAP-2, NAIP, 
apollon (BRUCE) and ML-IAP (LIVIN) and ILP-2 (Andersen et al., 2007). Among 
them, the most studied members of IAP gene family are XIAP, c-IAP1, c-IAP2 and 
Survivin (Rodríguez-Berriguete et al., 2010).  
 
Escape from apoptosis is one of the hallmarks of any tumor-initiating cell 
(Catalano et al., 2011). Among the inhibitors of apoptosis (IAP), interest recently 
focused on survivin, a structurally unique, bifunctional member of the IAP protein 
family, which is involved in the control of mitotic progression and inhibition of 
apoptosis (Altieri, 2001).  
 
2.6: Survivin 
               
Predicting disease outcome is very important in understanding the natural 
history of PCa, planning treatment strategies and counselling the patient.  It is also 
to examine and characterize tumors of poor prognosis, to predict their biology, to 
ensure adequate treatment and to improve patient outcome. One group of these 
possible factors is survivin, it inhibits apoptosis and regulates cell division and 
belongs to the inhibitors of apoptosis (IAP) gene family. 
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2.6.1: Survivin 
 
 Ambrosini et al. (1997) describe a new human gene encoding a structurally 
unique IAP apoptosis inhibitor that designated as survivin. Survivin is the smallest 
member of the IAP family, with a 142-amino acid, 16.5 kDa protein coded by a 
single-copy gene located on the human 17q25 chromosome. It plays critical role in 
cell division and anti-apoptosis (Mita et al., 2008). Compared to other IAPs, it is 
structurally unique, containing a single BIR domain and long carboxyl-terminus α-
helix, but there is no other identifiable protein domain (Altieri, 2010).  
 
Survivin present during fetal development but undetectable in most 
terminally differentiated adult tissues other than the thymus, placenta, CD34+ stem 
cells and basal epithelial cells (Ambrosini et al., 1997; Mita et al., 2008). It is a 
striking cancer gene which is abundantly expressed in almost human cancer tissues 
(Altieri, 2010). Overexpression of survivin has been reported in majority of cancers 
including esophageal, lung, breast, colon, gastric, pancreatic, cervical, bladder, 
uterus, ovary as well as prostate cancer (Fukuda and Pelus, 2006). The finding of 
recombinant expression of survivin counteracts apoptosis of B lymphocytes 
precursors deprived of interleukin 3 (IL-3) suggest that apoptosis inhibition may be a 
general feature of neoplasia and identify survivin as a potential new target for 
apoptosis-based therapy in cancer and lymphoma (Ambrosini et al., 1997). Before 
further discussion, we need to know the cell cycle and apoptotic process as survivin 
main functions are the regulation of cell division and the inhibition of apoptosis. 
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2.6.2: Cell cycle 
 
Cell cycle is the sequence of events that results in cell division (Mitchell, 
2015).  
 
 
 
Figure 2.7: Phases of the cell cycle. Outer ring: I=Interphase, M=Mitosis; inner ring: 
M=Mitosis, G1=Gap 1, G2=Gap 2, S=Synthesis; not in ring: G0=Gap 0/Resting. 
Source: (Wikipedia, 2015). 
 
The cell cycle consists of G1 (presynthetic growth), S (DNA synthesis), G2 
(premitotic growth) and M (mitotic) phases. G0 is a state where the quiescent cells 
that do not entered the cell cycle. M phase consists of prophase, metaphase, 
anaphase, telophase and cytokinesis (Wikipedia, 2015). Each cell cycle phase is 
